The central nervous system disorders therapeutics market share is expected to increase by USD 24.35 billion from 2020 to 2025, and the market's growth momentum will accelerate at a CAGR of 4.44%.

This central nervous system disorders therapeutics market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers central nervous system disorders therapeutics market segmentation by type (depression drugs, multiple sclerosis drugs, schizophrenia drugs, bipolar disorder therapeutics, epilepsy drugs, and others) and geography (Europe, North America, Asia, and ROW). The central nervous system disorders therapeutics market report also offers information on several market vendors, including AstraZeneca Plc, Boehringer Ingelheim International GmbH, Eli Lilly and Co., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Johnson and Johnson Inc., Merck and Co. Inc., Novartis AG, Otsuka Holdings Co. Ltd., and Pfizer Inc. among others.

What will the Central Nervous System Disorders Therapeutics Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the Central Nervous System Disorders Therapeutics Market Size for the Forecast Period and Other Important Statistics

Central Nervous System Disorders Therapeutics Market: Key Drivers, Trends, and Challenges

Based on our research output, there has been a neutral impact on the market growth during and post COVID-19 era. The increasing prevalence of CNS disorders is notably driving the central nervous system disorders therapeutics market growth, although factors such as high failure rates of late stage products in clinical trials may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the central nervous system disorders therapeutics industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Central Nervous System Disorders Therapeutics Market Driver

One of the key factors driving the central nervous system disorders therapeutics market growth is the increasing prevalence of CNS disorders. The increasing prevalence of CNS disorders such as depression, PD, AD, MS, epilepsy, and schizophrenia are expected to drive the growth of the global CNS disorder therapeutics market. For instance, according to the CDC, in 2015, about three million adults aged 18 years or above and 470,000 children aged 17 years or below had active epilepsy in the US. An estimated 17.3 million adults in the US had at least one major depressive episode in 2017. Schizophrenia is one of the top 15 leading causes of disability worldwide. The increasing prevalence of CNS disorders is driving the demand for effective therapeutics to treat CNS disorders, which is driving the growth of the global CNS disorder therapeutics market. The geriatric population is growing rapidly because of the increase in average life expectancy. The increase in the geriatric population will lead to a rise in the risk of developing several CNS disorders, thereby increasing the growth of the global CNS disorders therapeutics market.

Key Central Nervous System Disorders Therapeutics Market Trend

Increased uptake of new-generation drugs is the major trend influencing central nervous system disorders therapeutics market growth. The first-generation antiepileptic drugs such as phenobarbital, ethosuximide, primidone, phenytoin, carbamazepine, and valproic acid were in use for decades. However, these drugs are associated with many side effects, have narrow therapeutic ranges, and have complicated pharmacokinetics. Finally, new-generation of anti-epileptic drugs, which are the third-generation drugs, such as rufinamide, eslicarbazepine, retigabine, and lacosamide, have entered the market. Compared with the first-generation antiepileptic drugs, the new-generation drugs have very few side effects with wide therapeutic ranges; therefore, the uptake of new-generation antiepileptic drugs is higher. Second-generation anti-epileptic drugs find greater use compared with the third-generation drugs due to the slower incorporation of the latter into the treatment algorithm of epilepsy. The development of new-generation drugs with a more effective mechanism of action, coupled with fewer side actions, is expected to drive the growth of the market during the forecast period.

Key Central Nervous System Disorders Therapeutics Market Challenge

High failure rates of late stage products in clinical trials is one of the key challenges hindering the central nervous system disorders therapeutics market growth. Clinical research on CNS disorders is highly complicated and has a high failure rate compared with other therapy areas. Also, the regulatory bodies often recommend providing large clinical data regarding safety and efficacy profiles before approving drugs. The rising number of failures of clinical trials related to CNS disorder therapeutics acts as a major challenge for the growth of the global CNS disorder therapeutics market. For instance, in March 2020, UCB SA announced that its refractory epilepsy drug candidate padsevonil had failed a Phase 2b trial. The ARISE trial of padsevonil did not reach statistical significance for either of the two primary outcome measures, namely a reduction in seizure frequency over a 12-week follow-up period from the baseline; and the proportion of patients that achieved a 75% reduction in seizures.

This central nervous system disorders therapeutics market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2021-2025.

Who are the Major Central Nervous System Disorders Therapeutics Market Vendors?

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

• AstraZeneca Plc
• Boehringer Ingelheim International GmbH
• Eli Lilly and Co.
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline Plc
• Johnson and Johnson Inc.
• Merck and Co. Inc.
• Novartis AG
• Otsuka Holdings Co. Ltd.
• Pfizer Inc.

This statistical study of the central nervous system disorders therapeutics market encompasses successful business strategies deployed by the key vendors. The central nervous system disorders therapeutics market is fragmented and the vendors are deploying growth strategies such as focusing on developing novel drugs and forming strategic partnerships to compete in the market.

Product Insights and News

• Eli Lilly and Co. - The company offers Reyvow C V, 50 mg and 100 mg for central nervous system disorders therapeutics.

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The central nervous system disorders therapeutics market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Central Nervous System Disorders Therapeutics Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the central nervous system disorders therapeutics market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

The report has further elucidated on other innovative approaches being followed by vendors to ensure a sustainable market presence.

Which are the Key Regions for Central Nervous System Disorders Therapeutics Market?

For more insights on the market share of various regions Request for a FREE sample now!

42% of the market's growth will originate from North America during the forecast period. The US is one the key markets for central nervous system disorders therapeutics in North America. Market growth in this region will be slower than the growth of the market in Asia and Europe.

Factors such as the vendor's expertise in manufacturing high-quality and cost-efficient CNS drugs and their capability to develop advanced analytical capabilities will facilitate the central nervous system disorders therapeutics market growth in Europe over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

The growth of the central nervous system disorders therapeutics market in Europe has seen a rise during the COVID-19 pandemic. A study published in The Lancet finds that neurological diseases are the third common cause of disability and premature deaths and are estimated to increase with age in Europe. The growth of the market is also attributed to the efforts by market vendors to revamp their operations and recover from the negative impact of COVID-19, caused by the restrictive containment measures, such as social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. One of the significant trends that the market exhibits are mergers, acquisitions and partnerships. Many companies in the market involved in innovating CNS treatment drugs have entered into distribution and developmental agreements with fellow competitors. Strategies like these taken by the companies operating in the CNS disorders therapeutics market will significantly improve the prospects of the industry.

What are the Revenue-generating Type Segments in the Central Nervous System Disorders Therapeutics Market?

To gain further insights on the market contribution of various segments Request for a FREE sample

Market growth in the depression drugs segment will be significant during the forecast period. The growth is attributed to the increasing prevalence of depression and rising awareness campaigns on the problem. Additionally, the outbreak of COVID-19 has further resulted in increasing the prevalence of depression, further driving sales of anti-depressant drugs.

This report provides an accurate prediction of the contribution of all the segments to the growth of the central nervous system disorders therapeutics market size. This report provides an accurate prediction of the contribution of all the segments to the growth of the central nervous system disorders therapeutics market size and actionable market insights on post COVID-19 impact on each segment.

Request for a FREE sample

What are the Key Data Covered in this Central Nervous System Disorders Therapeutics Market Report?

• CAGR of the market during the forecast period 2021-2025
• Detailed information on factors that will drive central nervous system disorders therapeutics market growth during the next five years
• Precise estimation of the central nervous system disorders therapeutics market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the central nervous system disorders therapeutics industry across Europe, North America, Asia, and ROW
• A thorough analysis of the market's competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of central nervous system disorders therapeutics market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch